TNF and inflammatory bowel disease: Furthermore, no significant differences were observed when comparing HCs with IBD patients only treated with anti-TNFα agents, both in humoral immune response (1257 BAU/mL [744–2124] vs. 1676 BAU/mL [1156–2429]; p = 0.6] and in the QuantiFERON SARS-CoV-2 Ag1 (0.06 IU/mL [0.02–0.19] vs. 0.04 IU/mL [0.02–0.1]; p = 0.4) and Ag2 (0.09 IU/mL [0.03–0.26] vs. 0.07 IU/mL [0.03–0.14]; p = 0.6) responses, respectively (Figure 2).